- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05851560
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid or Parathyroid Surgery
Despite use of meticulous surgical techniques and regardless of surgical access via conventional open or endoscopy, postoperative adhesions develop in the vast majority of patients undergoing neck surgery. Such adhesions represent not only adhesion reformation at sites of adhesiolysis, but also de novo adhesion formation at sites of surgical procedures. Improved understanding of the pathophysiology of adhesion development and distinguishing variations in the molecular biologic mechanisms represent future opportunities to improve the reduction of postoperative adhesions.
After surgical tissue injury, there were local release of histamine, cytokines, and growth factors that lead to adhesion development. Other than survival or safety issues, cosmetics concerns and quality of life are the motifs after thyroid surgeries currently. Pos-thyroidectomy adhesions include various symptoms such as neck discomfort, neck tightness, skin adhesion to the trachea, skin scarring from adhesive reaction, and vocal cord palsy or impairment of laryngeal vertical movement. Relief of the adhesion through wound massage or anti-adhesion agents could reduce neck discomfort and voice changes.Although oxidized regenerated cellulose (ORC) and hyaluronic acid (HA) appeared to be safe and effective to decrease the incidence of adhesions, to improve adhesion-related neck discomfort, and to prevent skin adhesion to the trachea after neck surgery. The application of antiadhesive barriers after neck surgery is safe but the effect is still uncertain. Thus, we aim to confirm the antiadhesive effect of multiple antiadhesive barriers in thyroid/parathyroid surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The postsurgical adhesions remain a significant cause of morbidity for a large number of patients in thyroid and parathyroid surgeries, despite use of meticulous surgical techniques and regardless of surgical access via conventional open or endoscopy. Such adhesions represent not only adhesion reformation at sites of adhesiolysis, but also de novo adhesion formation at sites of surgical procedures. A number of products, in the form of film or fluid, are used to prevent postoperative adhesion formation. These products normally serve as barriers to separate the contact of the damaged tissue surfaces in many animal models and some clinical practices. However, there are few evidences for surgeons to use or no use, or choose the suitable products in their clinical practice in neck surgeries. Improved understanding of the pathophysiology of adhesion development and distinguishing variations in the molecular biologic mechanisms represent future opportunities to improve the reduction of postoperative adhesions.
After surgical tissue injury, there were local release of histamine, cytokines, and growth factors that lead to adhesion development . Local tissue inflammation processes initiate capillary leakage of serosanguineous fluid including clotting factors, and recruitment of macrophages and other cells, including fibroblasts. Cutting, fulguration, ligation of the macrovasculature and microvasculature leads to a state of tissue hypoxemia. Along with the accumulation of metabolic byproducts such as lactic acid, the lowering the pH of the injured tissue, and the conversion from aerobic to anaerobic metabolism within the injured tissues. Tissue hypoxia also results in creation of oxidative stress, with production of oxygen and nitrogen free radicals, which can result in DNA mutations, alterations of mitochondrial DNA, and generation of oxidized proteins.
Subsequently induce lipid peroxidation and protein nitration. The known factors involved in the inflammatory-like response that lead to adhesion development, are type 1 collagen, transforming growth factor b1 (TGF-b1), tumor necrosis factor a (TNF-a), interleukin 6 (IL-6), and vascular endothelial growth factor (VEGF). Of note, the scavenging of free radicals such as superoxide by superoxide dismutase can prevent the development of the adhesion phenotype . Other processes affected include plasminogen activator activity (PAA) (a function of tissue plasminogen activator and its inhibitor, plasminogen activator inhibitor-1), metalloproteinase activity, and extracellular matrix deposition (such as collagen 1, collagen 3, and fibronectin). There is also initiation of processes leading to angiogenesis, which can lead to new vessel formation that could resupply oxygen to these tissues as well as remove metabolic byproducts.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Ting-Chun Kuo
- Phone Number: 62557 +88623123456
- Email: tinakuo1204@gmail.com
Study Contact Backup
- Name: Ming Hsun Wu
- Phone Number: 71519 +88623123456
- Email: dtsurgp9@gmail.com
Study Locations
-
-
-
Taipei, Taiwan, 100229
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Ming Hsun Wu
- Phone Number: 71519 +886-2312-3456
- Email: dtsurg9@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age more than 20 years of age.
- Patients diagnosed with benign goiter or thyroid cancer that will undergo open thyroidectomy (either unilateral or bilateral total thyroidectomy with or without central lymph node dissection).
- Naïve patients to thyroid surgery.
- Subjects are willing to comply with all aspects of the study and have signed informed consent form.
Exclusion Criteria:
- Pregnant or lactating female patients.
- Presence of severe and uncontrolled illness such as stroke, hypertension, diabetes, chronic renal failure, coagulopathy.
- Concurrent diseases/conditions which will be unable to evaluate the outcomes.
- Patients with previous neck radiotherapy within 1 year.
- Patients receiving any adhesion prevention adjuvant.
- Previous history of Keloid or hypertrophic scar.
- Participate are hypersensitive to anti-adhesion agents.
- Participate in another clinical trial within 1 month.
- Participate have drug or alcohol abuse.
- Patients' presence of surgical site infection or uncontrolled bleeding.
- Anticoagulant used within a week from surger
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
control group that does not use antiadhesive material
|
|
Experimental: Oxidized regenerated cellulose(ORC) Group
The group that uses Oxidized regenerated cellulose(ORC) as antiadhesive material during thyroid surgery.
|
Investigate the antiadhesive effect of multiple antiadhesive barriers in thyroid surgery
Other Names:
|
Experimental: Hyaluronic acid(HA) Group
The group that uses Hyaluronic acid(HA) as antiadhesive material during thyroid surgery.
|
Hyaluronic acid(HA)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chinese version of Dysphagia Handicap Index(DHI)
Time Frame: pre-operation
|
Evaluate the swallowing difficulty
|
pre-operation
|
Chinese version of Dysphagia Handicap Index(DHI)
Time Frame: post-operation(week 2)
|
Evaluate the swallowing difficulty
|
post-operation(week 2)
|
Chinese version of Dysphagia Handicap Index(DHI)
Time Frame: post-operation( month1)
|
Evaluate the swallowing difficulty
|
post-operation( month1)
|
Chinese version of Dysphagia Handicap Index(DHI)
Time Frame: post-operation(month 6)
|
Evaluate the swallowing difficulty
|
post-operation(month 6)
|
Chinese version of Dysphagia Handicap Index(DHI)
Time Frame: post-operation( month12)
|
Evaluate the swallowing difficulty
|
post-operation( month12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adhesion severity
Time Frame: post-operation(week 2)
|
Evaluate the adhesion severity by using questionnaires
|
post-operation(week 2)
|
Adhesion severity
Time Frame: post-operation(month1)
|
Evaluate the adhesion severity by using questionnaires
|
post-operation(month1)
|
Adhesion severity
Time Frame: post-operation(month 6)
|
Evaluate the adhesion severity by using questionnaires
|
post-operation(month 6)
|
Adhesion severity
Time Frame: post-operation(month12)
|
Evaluate the adhesion severity by using questionnaires
|
post-operation(month12)
|
Collaborators and Investigators
Investigators
- Study Chair: Ming Hsun Wu, MD,PhD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202111057DINB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Goiter
-
Steen BonnemaCompleted
-
Genzyme, a Sanofi CompanyCompletedMultinodular GoiterCanada, United States, France, Brazil, Italy, Denmark, Germany, Netherlands
-
Cliniques universitaires Saint-Luc- Université...Completed
-
University Hospital, RouenCompletedGoiter, NodularFrance
-
Hospital Universitari de BellvitgeUnknown
-
Oklahoma State UniversityCompletedInfant Development | Iodine Deficiency GoiterEthiopia
-
Jagiellonian UniversityCompleted
-
Jan CalissendorffRecruiting
Clinical Trials on Oxidized regenerated cellulose(ORC)
-
Seoul National University HospitalCompletedThyroidectomyKorea, Republic of
-
Baxter Healthcare CorporationBaxter Innovations GmbHCompletedIntra-operative BleedingCzech Republic, Germany, Hungary, Poland
-
National Taiwan University HospitalUnknownPancreatic FistulaTaiwan
-
Catholic University of the Sacred HeartCompleted
-
Grifols Biologicals, LLCInstituto Grifols, S.A.CompletedSoft Tissue Surgical BleedingUnited States, Hungary, Serbia
-
Instituto Grifols, S.A.CompletedSafety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open SurgeriesParenchymous Tissue Surgical BleedingUnited States, Hungary, Russian Federation, Serbia
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Ethicon, Inc.OMRIX BiopharmaceuticalsCompletedBlood Loss, SurgicalUnited States
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue BleedingBelgium, Canada, United Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedParastomal HerniaSpain